Mesoblast

Mesoblast Interest Coverage

Interest Coverage Ratio of Mesoblast (MESO) as of Oct 18, 2026.

Interest Coverage

-

Last updated:

Interest Coverage Ratio of Mesoblast is 2026 - . Interest Coverage Ratio of Mesoblast was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Mesoblast Stock analysis

What does Mesoblast do? Mesoblast Ltd, based in Melbourne, Australia, develops regenerative medicine products using mesenchymal lineage cells. The company focuses on clinical-stage therapies such as Remestemcel-L for inflammatory conditions including graft versus host disease and inflammatory bowel disease, and MPC-300-IV for rheumatoid arthritis. It operates in Australia, the US, Singapore, and Switzerland with 81 employees and is listed on the stock exchange since 2015. Mesoblast is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Mesoblast stock

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Mesoblast since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Mesoblast with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Mesoblast

All Key Metrics — Mesoblast